Latest Hospitality News

EMVision Medical Devices reports strong clinical trial progress for its portable brain scanners, backed by solid cash reserves and milestone grant funding.

EMVision Medical Devices reports strong progress in its emu™ Brain Scanner clinical trials, expanding recruitment across seven leading stroke hospitals and introducing new software features to enhance scan quality.

Cyclopharm’s Technegas has been recognised as the preferred ventilation agent in a pivotal draft US lung imaging guideline, signalling a major boost for its adoption in American clinical practice.

A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

Pure Foods Tasmania has launched contract manufacturing with Brilliant Food Australia, marking a significant step in utilising its Woodbridge Smokehouse facility and expanding regional employment.

Anteris Technologies Global Corp. has launched a $230 million equity offering alongside an $84 million private placement with Medtronic’s subsidiary, aiming to accelerate clinical trials and scale manufacturing of its innovative DurAVR Transcatheter Heart Valve.

Osteopore Limited has inked a three-year exclusive distribution agreement with MontsMed to introduce its advanced orthopaedic trauma reconstruction products into Hong Kong, positioning itself strategically within the Greater Bay Area.

The Garvan Institute has won a $3 million MRFF grant to conduct pivotal pancreatic cancer studies, including one evaluating Syntara’s amsulostat combined with chemotherapy. Recruitment is slated to begin mid-2026 across major NSW cancer centres.

Imricor Medical Systems has secured Virginia Commonwealth University Health as the third US site for its VISABL-AFL clinical trial, advancing its FDA approval pathway for MRI-guided cardiac ablation technology.

Firebrick Pharma has introduced its Nasodine Throat Spray in Singapore, marking its first international product launch and setting the stage for further global rollouts in 2026.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.